Endurant Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Endurant Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-206,800	Closed	-$36.3M	–	86
2021 Q3	$36.3M	Buy	+206,800	New	+$2.42M	8.27%	3

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Endurant Capital Management's TRIL Position: Q3 2021 in Review

Endurant Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 600,788 shares — an estimated $7.02M sold.

Endurant Capital Management first reported a position in TRIL in Q4 2015 and held it in 10 quarters. The position peaked at $9.65M in Q4 2020. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

Endurant Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
Endurant Capital Management sold 600,788 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $7.02M.
Endurant Capital Management first reported a position in Trillium Therapeutics Inc. in Q4 2015 and held it in 10 quarters.
Endurant Capital Management's Trillium Therapeutics Inc. position peaked at $9.65M in Q4 2020.
182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.